MDM2 non-genotoxic inhibitors as innovative therapeutic approaches for the treatment of pediatric malignancies

Current Medicinal Chemistry

Volumn 20, Issue 17, 2013, Pages 2226-2236

  Tisato, V ^a   Norcio, A ^b   Voltan, R ^a   Celeghini, C ^c   Zella, D ^d   Secchiero, P ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical perspectives; Innovative therapeutic combinations; MDM2 inhibitors; Non genotoxic inhibitors; Nutlins family; P53; Pediatric preclinical testing program; Pediatric tumors

Indexed keywords

BEVACIZUMAB; CISPLATIN; CYTARABINE; DOXORUBICIN; HLI 373; HLI 98; IMATINIB; IMIDAZOLINE DERIVATIVE; LIGASE; LIGASE INHIBITOR; METHOTREXATE; MI 147; MI 219; MI 63; NUTLIN 1; NUTLIN 2; NUTLIN 3; NXN 561; NXN 7; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN MDM2 INHIBITOR; PROTEIN P53; RG 7112; RITA; RO 5045337; SERDEMETAN; TDP 521252; TDP 665759; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; ADVANCED SOLID TUMOR; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; CANCER CHEMOTHERAPY; CHILDHOOD CANCER; COGNITIVE DEFECT; DRUG DESIGN; DRUG IDENTIFICATION; ENZYME ACTIVITY; EWING SARCOMA; GASTROINTESTINAL STROMAL TUMOR; HEMATOLOGIC NEOPLASM; HUMAN; IC 50; LIPOSARCOMA; MEDULLOBLASTOMA; MENTAL DISEASE; MOTOR DYSFUNCTION; NEOPLASM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PROTEIN BINDING; RETINOBLASTOMA; RHABDOMYOSARCOMA; SOLID TUMOR; WILD TYPE;

CHILD; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; NEOPLASMS; PIPERAZINES; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTO-ONCOGENE PROTEINS C-MDM2; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84877954290     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320170007     Document Type: Article

References (127)

1. Meek, D.W. Tumour suppression by p53: A role for the DNA damage response? Nat. Rev. Cancer, 2009, 9(10), 714-723.
2. Green, D.R.; Kroemer, G. Cytoplasmic functions of the tumour suppressor p53. Nature, 2009, 458(7242), 1127-1130.
3. Teodoro, J.G.; Evans, S.K.; Green, M.R. Inhibition of tumor angiogenesis by p53: A new role for the guardian of the genome. J. Mol. Med. (Berl.), 2007, 85(11), 1175-1186. (Pubitemid 47622219)
4. Vousden, K.H.; Lu, X. Live or let die: The cell's response to p53. Nat. Rev. Cancer, 2002, 2(8), 594-604. (Pubitemid 37328926)
5. Weinberg, R.A. The retinoblastoma protein and cell cycle control. Cell, 1995, 81(3), 323-330.
6. Joerger, A.C.; Fersht, A.R. Structural biology of the tumor suppressor p53. Annu. Rev. Biochem., 2008, 77, 557-582.
7. Yoshida, K.; Miki, Y. The cell death machinery governed by the p53 tumor suppressor in response to DNA damage. Cancer Sci., 2010, 101(4), 831-835.
8. Vazquez, A.; Bond, E.E.; Levine, A.J.; Bond, G.L. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat. Rev. Drug. Discov., 2008, 7(12), 979-987.
9. Riley, T.; Sontag, E.; Chen, P.; Levine, A. Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell. Biol., 2008, 9(5), 402-412. (Pubitemid 351574202)
10. Hainaut, P.; Hollstein, M. p53 and human cancer: The first ten thousand mutations. Adv. Cancer Res., 2000, 77, 81-137. (Pubitemid 29439303)
11. Rivlin, N.; Brosh, R.; Oren, M.; Rotter, V. Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. Genes Cancer, 2011, 2(4), 466-474.
12. Wiman, K.G. Restoration of wild-type p53 function in human tumors: Strategies for efficient cancer therapy. Adv. Cancer Res., 2007, 97, 321-338. (Pubitemid 46528994)
13. Beaudry, G.A.; Bertelsen, A.H.; Sherman, M.I. Therapeutic targeting of the p53 tumor suppressor gene. Curr. Opin. Biotechnol., 1996, 7(6), 592-600. (Pubitemid 26400061)
14. Mandinova, A.; Lee, S.W. The p53 pathway as a target in cancer therapeutics: Obstacles and promise. Sci. Transl. Med., 2011, 3(64), 64rv1.
15. Ventura, A.; Kirsch, D.G.; McLaughlin, M.E.; Tuveson, D.A.; Grimm, J.; Lintault, L.; Newman, J.; Reczek, E. E.; Weissleder, R.; Jacks, T. Restoration of p53 function leads to tumour regression in vivo. Nature, 2007, 445(7128), 661-665. (Pubitemid 46232887)
16. Martins, C.P.; Brown-Swigart, L.; Evan, G.I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell, 2006, 127(7), 1323-1334. (Pubitemid 44960417)
17. Kastan, M.B. Wild-type p53: Tumors can't stand it. Cell, 2007, 128(5), 837-840. (Pubitemid 46341421)
18. Oliner, J.D.; Pietenpol, J.A.; Thiagalingam, S.; Gyuris, J.; Kinzler, K.W.; Vogelstein, B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature, 1993, 362(6423), 857-860. (Pubitemid 23132165)
19. Momand, J.; Zambetti, G.P.; Olson, D.C.; George, D.; Levine, A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 1992, 69(7), 1237-1245.
20. Momand, J.; Jung, D.; Wilczynski, S.; Niland, J. The MDM2 gene amplification database. Nucleic Acids Res., 1998, 26(15), 3453-3459. (Pubitemid 28347214)
21. Onel, K.; Cordon-Cardo, C. MDM2 and prognosis. Mol. Cancer Res., 2004, 2(1), 1-8. (Pubitemid 38167102)
22. Montes de Oca Luna, R.; Wagner, D.S.; Lozano, G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature, 1995, 378(6553), 203-206.
23. Parant, J.; Chavez-Reyes, A.; Little, N.A.; Yan, W.; Reinke, V.; Jochemsen, A.G.; Lozano, G. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat. Genet., 2001, 29(1), 92-95. (Pubitemid 32801817)
24. de Rozieres, S.; Maya, R.; Oren, M.; Lozano, G. The loss of mdm2 induces p53-mediated apoptosis. Oncogene, 2000, 19(13), 1691-1697. (Pubitemid 30200971)
25. Chavez-Reyes, A.; Parant, J.M.; Amelse, L.L.; de Oca Luna, R.M.; Korsmeyer, S.J.; Lozano, G. Switching mechanisms of cell death in mdm2-and mdm4-null mice by deletion of p53 downstream targets. Cancer Res., 2003, 63(24), 8664-8669. (Pubitemid 38064041)
26. Steinman, H.A.; Burstein, E.; Lengner, C.; Gosselin, J.; Pihan, G.; Duckett, C.S.; Jones, S.N. An alternative splice form of Mdm2 induces p53-independent cell growth and tumorigenesis. J. Biol. Chem., 2004, 279(6), 4877-4886. (Pubitemid 38199083)
27. Zhang, Z.; Zhang, R. p53-independent activities of MDM2 and their relevance to cancer therapy. Curr. Cancer Drug. Targets, 2005, 5(1), 9-20. (Pubitemid 40321796)
28. Wu, X.; Bayle, J.H.; Olson, D.; Levine, A.J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev., 1993, 7(7A), 1126-1132. (Pubitemid 23207405)
29. Freedman, D.A.; Levine, A.J. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell Biol., 1998, 18(12), 7288-7293. (Pubitemid 28533048)
30. Kubbutat, M.H.; Jones, S.N.; Vousden, K.H. Regulation of p53 stability by Mdm2. Nature, 1997, 387(6630), 299-303. (Pubitemid 27220767)
31. Haupt, Y.; Maya, R.; Kazaz, A.; Oren, M., Mdm2 promotes the rapid degradation of p53. Nature, 1997, 387(6630), 296-299. (Pubitemid 27220766)
32. Jain, A.K.; Barton, M.C., Making sense of ubiquitin ligases that regulate p53. Cancer Biol. Ther., 2010, 10(7), 665-672.
33. Shvarts, A.; Steegenga, W.T.; Riteco, N.; van Laar, T.; Dekker, P.; Bazuine, M.; van Ham, R. C.; van der Houven van Oordt, W.; Hateboer, G.; van der Eb, A.J.; Jochemsen, A.G., MDMX: A novel p53-binding protein with some functional properties of MDM2. EMBO J., 1996, 15(19), 5349-5357. (Pubitemid 26336217)
34. Shvarts, A.; Bazuine, M.; Dekker, P.; Ramos, Y.F.; Steegenga, W.T.; Merckx, G.; van Ham, R.C.; van der Houven van Oordt, W.; van der Eb, A.J.; Jochemsen, A.G. Isolation and identification of the human homolog of a new p53-binding protein, Mdmx. Genomics, 1997, 43(1), 34-42. (Pubitemid 27310520)
35. Francoz, S.; Froment, P.; Bogaerts, S.; De Clercq, S.; Maetens, M.; Doumont, G.; Bellefroid, E.; Marine, J.C. Mdm4 and Mdm2 coop erate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc. Natl. Acad. Sci. U S A, 2006, 103(9), 3232-3237. (Pubitemid 43346453)
36. Tanimura, S.; Ohtsuka, S.; Mitsui, K.; Shirouzu, K.; Yoshimura, A.; Ohtsubo, M. MDM2 interacts with MDMX through their RING finger domains. F.E.B.S. Lett., 1999, 447(1), 5-9. (Pubitemid 29134936)
37. Shadfan, M.; Lopez-Pajares, V.; Yuan, Z.M. MDM2 and MDMX: Alone and together in regulation of p53. Transl. Cancer Res., 2012, 1(2), 88-89.
38. Lenos, K.; Jochemsen, A.G. Functions of MDMX in the modulation of the p53-response. J. Biomed. Biotechnol., 2011, 2011, 876173.
39. Marine, J.C.; Jochemsen, A.G. Mdmx as an essential regulator of p53 activity. Biochem. Biophys. Res. Commun., 2005, 331(3), 750-760. (Pubitemid 40615506)
40. Marine, J. C.; Jochemsen, A. G. Mdmx and Mdm2: Brothers in arms? Cell Cycle, 2004, 3(7), 900-904. (Pubitemid 40179469)
41. Pazgier, M.; Liu, M.; Zou, G.; Yuan, W.; Li, C.; Li, J.; Monbo, J.; Zella, D.; Tarasov, S.G.; Lu, W. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc. Natl. Acad. Sci. U S A, 2009, 106(12), 4665-4670.
42. Danovi, D.; Meulmeester, E.; Pasini, D.; Migliorini, D.; Capra, M.; Frenk, R.; de Graaf, P.; Francoz, S.; Gasparini, P.; Gobbi, A.; Helin, K.; Pelicci, P.G.; Jochemsen, A.G.; Marine, J.C. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol. Cell. Biol., 2004, 24(13), 5835-5843. (Pubitemid 38787968)
43. Chen, J.; Marechal, V.; Levine, A.J. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell Biol., 1993, 13(7), 4107-4114. (Pubitemid 23187639)
44. Kussie, P.H.; Gorina, S.; Marechal, V.; Elenbaas, B.; Moreau, J.; Levine, A.J.; Pavletich, N.P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science, 1996, 274(5289), 948-953. (Pubitemid 26398409)
45. Shin, J.S.; Ha, J.H.; He, F.; Muto, Y.; Ryu, K.S.; Yoon, H.S.; Kang, S.; Park, S.G.; Park, B.C.; Choi, S.U.; Chi, S.W. Structural insights into the dual-targeting mechanism of Nutlin-3. Biochem. Biophys. Res. Commun., 2012, 420(1), 48-53.
46. Ha, J.H.; Won, E.Y.; Shin, J.S.; Jang, M.; Ryu, K.S.; Bae, K.H.; Park, S.G.; Park, B.C.; Yoon, H.S.; Chi, S.W. Molecular mimicrybased repositioning of nutlin-3 to anti-apoptotic Bcl-2 family proteins. J. Am. Chem. Soc., 2011, 133(5), 1244-1247.
47. Yu, G.W.; Rudiger, S.; Veprintsev, D.; Freund, S.; Fernandez-Fernandez, M.R.; Fersht, A.R. The central region of HDM2 provides a second binding site for p53. Proc. Natl. Acad. Sci. U S A, 2006, 103(5), 1227-1232. (Pubitemid 43191147)
48. Lauria, A.; Tutone, M.; Ippolito, M.; Pantano, L.; Almerico, A.M. Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: The investigation of p53-MDM2 interaction and its inhibition by small molecules. Curr. Med. Chem., 2010, 17(28), 3142-3154.
49. Koes, D.; Khoury, K.; Huang, Y.; Wang, W.; Bista, M.; Popowicz, G.M.; Wolf, S.; Holak, T.A.; Domling, A.; Camacho, C.J. Enabling large-scale design, synthesis and validation of small molecule protein-protein antagonists. PloS One, 2012, 7(3), e32839.
50. Reynes, C.; Host, H.; Camproux, A.C.; Laconde, G.; Leroux, F.; Mazars, A.; Deprez, B.; Fahraeus, R.; Villoutreix, B.O.; Sperandio, O. Designing focused chemical libraries enriched in protein-protein interaction inhibitors using machine-learning methods. PLoS Comput. Biol., 2010, 6(3), e1000695.
51. Sperandio, O.; Reynes, C.H.; Camproux, A.C.; Villoutreix, B.O. Rationalizing the chemical space of protein-protein interaction inhibitors. Drug Discov. Today, 2010, 15(5-6), 220-229.
52. Fang, S.; Jensen, J. P.; Ludwig, R. L.; Vousden, K. H.; Weissman, A. M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem., 2000, 275(12), 8945-8951. (Pubitemid 30180252)
53. Yang, Y.; Ludwig, R.L.; Jensen, J.P.; Pierre, S.A.; Medaglia, M.V.; Davydov, I.V.; Safiran, Y.J.; Oberoi, P.; Kenten, J.H.; Phillips, A.C.; Weissman, A.M.; Vousden, K.H. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell, 2005, 7(6), 547-559. (Pubitemid 40799248)
54. Kitagaki, J.; Agama, K.K.; Pommier, Y.; Yang, Y.; Weissman, A.M. Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2. Mol. Cancer Ther., 2008, 7(8), 2445-2454.
55. Kojima, K.; Burks, J.K.; Arts, J.; Andreeff, M. The novel tryptamine derivative JNJ-26854165 induces wild-type p53-and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias. Mol. Cancer Ther., 2010, 9(9), 2545-2557.
56. Tabernero, J.; Dirix, L.; Schoffski, P.; Cervantes, A.; Lopez-Martin, J.A.; Capdevila, J.; van Beijsterveldt, L.; Platero, S.; Hall, B.; Yuan, Z.; Knoblauch, R.; Zhuang, S.H. A phase I first-inhuman pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors. Clin. Cancer Res., 2011, 17(19), 6313-6321.
57. Issaeva, N.; Bozko, P.; Enge, M.; Protopopova, M.; Verhoef, L.G.; Masucci, M.; Pramanik, A.; Selivanova, G. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med., 2004, 10(12), 1321-1328. (Pubitemid 40022713)
58. Krajewski, M.; Ozdowy, P.; D'Silva, L.; Rothweiler, U.; Holak, T.A. NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro. Nat. Med., 2005, 11(11), 1135-6; author reply 1136-1137.
59. Vassilev, L.T.; Vu, B.T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E.A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science, 2004, 303(5659), 844-848. (Pubitemid 38174664)
60. Millard, M.; Pathania, D.; Grande, F.; Xu, S.; Neamati, N. Smallmolecule inhibitors of p53-MDM2 interaction: The 2006-2010 update. Curr. Pharm. Des., 2011, 17(6), 536-559.
61. Koblish, H.K.; Zhao, S.; Franks, C.F.; Donatelli, R.R.; Tominovich, R.M.; LaFrance, L.V.; Leonard, K.A.; Gushue, J.M.; Parks, D.J.; Calvo, R.R.; Milkiewicz, K.L.; Marugan, J.J.; Raboisson, P.; Cummings, M.D.; Grasberger, B.L.; Johnson, D.L.; Lu, T.; Molloy, C.J.; Maroney, A.C. Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. Mol. Cancer Ther., 2006, 5(1), 160-169.
62. Ding, K.; Lu, Y.; Nikolovska-Coleska, Z.; Wang, G.; Qiu, S.; Shangary, S.; Gao, W.; Qin, D.; Stuckey, J.; Krajewski, K.; Roller, P.P.; Wang, S. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J. Med. Chem., 2006, 49 (12), 3432-3435. (Pubitemid 43902447)
63. Ding, K.; Lu, Y.; Nikolovska-Coleska, Z.; Qiu, S.; Ding, Y.; Gao, W.; Stuckey, J.; Krajewski, K.; Roller, P.P.; Tomita, Y.; Parrish, D.A.; Deschamps, J.R.; Wang, S. Structure-based design of potent non-peptide MDM2 inhibitors. J. Am. Chem. Soc., 2005, 127(29), 10130-10131. (Pubitemid 41045454)
64. Shangary, S.; Qin, D.; McEachern, D.; Liu, M.; Miller, R.S.; Qiu, S.; Nikolovska-Coleska, Z.; Ding, K.; Wang, G.; Chen, J.; Bernard, D.; Zhang, J.; Lu, Y.; Gu, Q.; Shah, R.B.; Pienta, K.J.; Ling, X.; Kang, S.; Guo, M.; Sun, Y.; Yang, D.; Wang, S. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc. Natl. Acad. Sci. U S A, 2008, 105(10), 3933-3938. (Pubitemid 351723502)
65. Mohammad, R.M.; Wu, J.; Azmi, A. S.; Aboukameel, A.; Sosin, A.; Wu, S.; Yang, D.; Wang, S.; Al-Katib, A. M. An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. Mol. Cancer, 2009, 8, 115.
66. Rothweiler, U.; Czarna, A.; Krajewski, M.; Ciombor, J.; Kalinski, C.; Khazak, V.; Ross, G.; Skobeleva, N.; Weber, L.; Holak, T.A. Isoquinolin-1-one inhibitors of the MDM2-p53 interaction. Chem. Med. Chem., 2008, 3(7), 1118-1128.
67. Ringshausen, I.; O'Shea, C.C.; Finch, A.J.; Swigart, L.B.; Evan, G.I. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell, 2006, 10(6), 501-514. (Pubitemid 44854749)
68. Shangary, S.; Ding, K.; Qiu, S.; Nikolovska-Coleska, Z.; Bauer, J.A.; Liu, M.; Wang, G.; Lu, Y.; McEachern, D.; Bernard, D.; Bradford, C.R.; Carey, T.E.; Wang, S. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. Mol Cancer Ther., 2008, 7(6), 1533-1542.
69. Kumamoto, K.; Spillare, E.A.; Fujita, K.; Horikawa, I.; Yamashita, T.; Appella, E.; Nagashima, M.; Takenoshita, S.; Yokota, J.; Harris, C. C. Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res., 2008, 68(9), 3193-3203.
70. Mendrysa, S.M.; O'Leary, K.A.; McElwee, M.K.; Michalowski, J.; Eisenman, R.N.; Powell, D.A.; Perry, M.E. Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev., 2006, 20(1), 16-21. (Pubitemid 43042663)
71. Gu, L.; Zhu, N.; Findley, H.W.; Zhou, M. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblas tic leukemia cells with wild-type p53 and overexpression of MDM2. Leukemia, 2008, 22(4), 730-739. (Pubitemid 351552622)
72. Ghassemifar, S.; Mendrysa, S.M. MDM2 antagonism by nutlin-3 induces death in human medulloblastoma cells. Neurosci. Lett., 2012, 513(1), 106-110.
73. Barbieri, E.; Mehta, P.; Chen, Z.; Zhang, L.; Slack, A.; Berg, S.; Shohet, J.M. MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Mol. Cancer Ther., 2006, 5(9), 2358-2365. (Pubitemid 44530473)
74. Tovar, C.; Rosinski, J.; Filipovic, Z.; Higgins, B.; Kolinsky, K.; Hilton, H.; Zhao, X.; Vu, B.T.; Qing, W.; Packman, K.; Myklebost, O.; Heimbrook, D.C.; Vassilev, L.T. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy. Proc. Natl. Acad. Sci. U S A, 2006, 103(6), 1888-1893. (Pubitemid 43228788)
75. Secchiero, P.; Zerbinati, C.; Melloni, E.; Milani, D.; Campioni, D.; Fadda, R.; Tiribelli, M.; Zauli, G. The MDM-2 antagonist Nutlin-3 promotes maturation of acute myeloid leukemic blasts. Neoplasia, 2007, 9(10) 853-861. (Pubitemid 47623425)
76. Secchiero, P.; di Iasio, M.G.; Gonelli, A.; Zauli, G. The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies. Curr. Pharm. Des., 2008, 14(21), 2100-2110.
77. Secchiero, P.; Bosco, R.; Celeghini, C.; Zauli, G. Recent advances in the therapeutic perspectives in nutlin-3. Curr. Pharm. Des., 2011, 17(6), 569-577.
78. Ray, R.M.; Bhattacharya, S.; Johnson, L.R. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73-and E2F1-mediated expression of PUMA and Siva-1. Apoptosis, 2011, 16(1), 35-44.
79. Brosh, R.; Rotter, V. When mutants gain new powers: News from the mutant p53 field. Nat. Rev. Cancer, 2009, 9(10), 701-713.
80. Patton, J.T.; Mayo, L.D.; Singhi, A.D.; Gudkov, A.V.; Stark, G.R.; Jackson, M.W. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res., 2006, 66(6), 3169-3176.
81. Kusafuka, T.; Fukuzawa, M.; Oue, T.; Komoto, Y.; Yoneda, A.; Okada, A. Mutation analysis of p53 gene in childhood malignant solid tumors. J. Pediatr. Surg., 1997, 32(8), 1175-1180. (Pubitemid 27475893)
82. Matthay, K.K.; George, R.E.; Yu, A.L. Promising therapeutic targets in neuroblastoma. Clin. Cancer Res., 2012, 18(10), 2740-2753.
83. Tweddle, D.A.; Pearson, A.D.; Haber, M.; Norris, M.D.; Xue, C.; Flemming, C.; Lunec, J. The p53 pathway and its inactivation in neuroblastoma. Cancer Lett., 2003, 197(1-2), 93-98. (Pubitemid 36859996)
84. Van Maerken, T.; Ferdinande, L.; Taildeman, J.; Lambertz, I.; Yigit, N.; Vercruysse, L.; Rihani, A.; Michaelis, M.; Cinatl, J., Jr.; Cuvelier, C.A.; Marine, J.C.; De Paepe, A.; Bracke, M.; Speleman, F.; Vandesompele, J. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistantneuroblastoma with wildtype p53. J. Natl. Cancer Inst., 2009, 101(22), 1562-1574.
85. Pistoia, V.; Morandi, F.; Pezzolo, A.; Raffaghello, L.; Prigione, I. MYCN: From oncoprotein to tumor-associatedantigen. Front. Oncol., 2012, 2, 174.
86. Gamble, L.D.; Kees, U.R.; Tweddle, D.A.;Lunec, J. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63. Oncogene, 2012, 31(6), 752-763.
87. Petroni, M.; Veschi, V.; Gulino, A.; Giannini, G. Molecular mechanisms of MYCN-dependent apoptosis and the MDM2-p53 pathway: An Achille's heel to be exploited for the therapy of MYCN-amplified neuroblastoma. Front. Oncol., 2012, 2, 141.
88. Miyachi, M.; Kakazu, N.; Yagyu, S.; Katsumi, Y.; Tsubai-Shimizu, S.; Kikuchi, K.; Tsuchiya, K.; Iehara, T.; Hosoi, H. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells. Clin. Cancer Res., 2009, 15(12), 4077-4084.
89. Canner, J.A.; Sobo, M.; Ball, S.; Hutzen, B.; DeAngelis, S.; Willis, W.; Studebaker, A.W.; Ding, K.; Wang, S.; Yang, D.; Lin, J. MI-63: A novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53. Br. J. Cancer, 2009, 101(5), 774-781.
90. Rickert, C.H.; Paulus, W. Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification. Childs Nerv. Syst., 2001, 17(9), 503-511. (Pubitemid 32842704)
91. Kunkele, A.; De Preter, K.; Heukamp, L.; Thor, T.; Pajtler, K. W.; Hartmann, W.; Mittelbronn, M.; Grotzer, M.A.; Deubzer, H.E.; Speleman, F.; Schramm, A.; Eggert, A.; Schulte, J.H. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas. NeuroOncol., 2012, 14(7), 859-869.
92. Zhu, N.; Gu, L.; Li, F.; Zhou, M. Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells. Mol. Cancer Ther., 2008, 7(5), 1101-1109.
93. Radig, K.; Schneider-Stock, R.; Rose, I.; Mittler, U.; Oda, Y.; Roessner, A. p53 and ras mutations in Ewing's sarcoma. Pathol. Res. Pract., 1998, 194(3), 157-162. (Pubitemid 28192782)
94. Pishas, K.I.; Al-Ejeh, F.; Zinonos, I.; Kumar, R.; Evdokiou, A.; Brown, M.P.; Callen, D.F.; Neilsen, P.M. Nutlin-3a is a potential therapeutic for ewing sarcoma. Clin. Cancer Res., 2011, 17(3), 494-504.
95. Sonnemann, J.; Palani, C.D.; Wittig, S.; Becker, S.; Eichhorn, F.; Voigt, A.; Beck, J.F. Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells. Eur. J. Cancer, 2011, 47(9), 1432-1441.
96. Di Conza, G.; Buttarelli, M.; Monti, O.; Pellegrino, M.; Mancini, F.; Pontecorvi, A.; Scotlandi, K.; Moretti, F. IGF-1R/MDM2 relationship confers enhanced sensitivity to RITA in Ewing sarcoma cells. Mol. Cancer Ther., 2012, 11(6), 1247-1256.
97. Laurie, N.A.; Donovan, S.L.; Shih, C.S.; Zhang, J.; Mills, N.; Fuller, C.; Teunisse, A.; Lam, S.; Ramos, Y.; Mohan, A.; Johnson, D.; Wilson, M.; Rodriguez-Galindo, C.; Quarto, M.; Francoz, S.; Mendrysa, S.M.; Guy, R.K.; Marine, J.C.; Jochemsen, A. G.; Dyer, M. A. Inactivation of the p53 pathway in retinoblastoma. Nature, 2006, 444(7115), 61-66. (Pubitemid 44684754)
98. Brennan, R.C.; Federico, S.; Bradley, C.; Zhang, J.; Flores-Otero, J.; Wilson, M.; Stewart, C.; Zhu, F.; Guy, K.; Dyer, M.A. Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a. Cancer Res., 2011, 71(12), 4205-4213.
99. Zou, P.; Zheng, N.; Yu, Y.; Yu, S.; Sun, W.; McEachem, D.; Yang, Y.; Yu, L.X.; Wang, S.; Sun, D. Preclinical pharmacokinetics of MI-219, a novel human double minute 2 (HDM2) inhibitor and prediction of human pharmacokinetics. J. Pharm. Pharm. Sci., 2012, 15(2), 265-280.
100. Zhang, F.; Tagen, M.; Throm, S.; Mallari, J.; Miller, L.; Guy, R.K.; Dyer, M.A.; Williams, R.T.; Roussel, MF.; Nemeth, K.; Zhu, F.; Zhang, J.; Lu, M.; Panetta, J.C.; Boulos, N.; Stewart, C.F. Wholebody physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration. Drug. Metab. Dispos., 2011, 39(1), 15-21.
101. Beck, H.P.; De Graffenreid, M.; Fox, B.; Allen, J.G.; Rew, Y.; Schneider, S.; Saiki, A.Y.; Yu, D.; Oliner, J.D.; Salyers, K.; Ye, Q.; Olson, S. Improvement of the synthesis and pharmacokinetic properties of chromenotriazolopyrimidine MDM2-p53 protein-protein inhibitors. Bioorg. Med. Chem. Lett., 2011, 21(9), 2752-2755.
102. Peirce, S.K.; Findley, H.W. The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73. Int. J. Oncol., 2009, 34(5), 1395-1402.
103. Patterson, D.M.; Gao, D.; Trahan, D.N.; Johnson, B.A.; Ludwig, A.; Barbieri, E.; Chen, Z.; Diaz-Miron, J.; Vassilev, L.; Shohet, J.M.; Kim, E.S. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma. Angiogenesis, 2011, 14(3), 255-266.
104. Secchiero, P.; Melloni, E.; di Iasio, M.G.; Tiribelli, M.; Rimondi, E.; Corallini, F.; Gattei, V.; Zauli, G. Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. Blood, 2009, 113(18), 4300-4308.
105. Zauli, G.; Celeghini, C.; Melloni, E.; Voltan, R.; Ongari, M.; Tiribelli, M.; di Iasio, M.G.; Lanza, F.; Secchiero, P. The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. Haematologica, 2012, 97(11), 1722-1730.
106. Kojima, K.; Konopleva, M.; McQueen, T.; O'Brien, S.; Plunkett, W.; Andreeff, M. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood, 2006, 108(3), 993-1000. (Pubitemid 44154636)
107. Zauli, G.; Voltan, R.; Bosco, R.; Melloni, E.; Marmiroli, S.; Rigolin, G. M.; Cuneo, A.; Secchiero, P. Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway. Clin. Cancer Res., 2011, 17(4), 762-770.
108. Secchiero, P.; Gonelli, A.; Celeghini, C.; Mirandola, P.; Guidotti, L.; Visani, G.; Capitani, S., Zauli, G. Activation of the nitric oxide synthase pathway represents a key component of tumor necrosis factor-related apoptosis-inducing ligand-mediated cytotoxicity on hematologic malignancies. Blood, 2001, 98(7), 2220-2228.
109. Secchiero, P.; Zauli, G. Tumor-necrosis-factor-related apoptosisinducing ligand and the regulation of hematopoiesis. Curr. Opin. Hematol., 2008, 15(1), 42-48. (Pubitemid 350191027)
110. Secchiero, P.; Zerbinati, C.; di Iasio, M.G.; Melloni, E.; Tiribelli, M.; Grill, V.; Zauli, G. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr. Drug Metab., 2007, 8(4), 395-403. (Pubitemid 46780067)
111. Secchiero, P.; Corallini, F.; Rimondi, E.; Chiaruttini, C.; di Iasio, M.G.; Rustighi, A.; Del Sal, G.; Zauli, G. Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells. Blood, 2008, 111(3), 1287-1294. (Pubitemid 351213412)
112. Zauli, G.; Corallini, F.; Bossi, F.; Fischetti, F.; Durigutto, P.; Celeghini, C.; Tedesco, F.; Secchiero, P. Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood, 2007, 110(2), 536-543. (Pubitemid 47105391)
113. Zauli, G.; Melloni, E.; Capitani, S.; Secchiero, P. Role of fulllength osteoprotegerin in tumor cell biology. Cell. Mol. Life Sci., 2009, 66(5), 841-851.
114. Secchiero, P.; Corallini, F.; Beltrami, A.P.; Ceconi, C.; Bonasia, V.; Di Chiara, A.; Ferrari, R.; Zauli, G. An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis, 2010, 210(1), 274-277.
115. Opel, D.; Naumann, I.; Schneider, M.; Bertele, D.; Debatin, K. M.; Fulda, S. Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma. Clin. Cancer Res., 2011, 17(10), 3233-3247.
116. Milani, D.; Zauli, G.; Rimondi, E.; Celeghini, C.; Marmiroli, S.; Narducci, P.; Capitani, S.; Secchiero, P. Tumour necrosis factorrelated apoptosis-inducing ligand sequentially activates prosurvival and pro-apoptotic pathways in SK-N-MC neuronal cells. J. Neurochem., 2003, 86(1), 126-135. (Pubitemid 36753853)
117. Samudio, I.J.; Duvvuri, S.; Clise-Dwyer, K.; Watt, J.C.; Mak, D.; Kantarjian, H.; Yang, D.; Ruvolo, V.; Borthakur, G. Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells. Leuk. Lymphoma, 2010, 51(5), 911-919.
118. Ohnstad, H.O.; Paulsen, E.B.; Noordhuis, P.; Berg, M.; Lothe, R.A.; Vassilev, L.T.; Myklebost, O. MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines. BMC Cancer, 2011, 11, 211:1-211.
119. Muret, J.; Hasmim, M.; Stasik, I.; Jalil, A.; Mallavialle, A.; Nanbakhsh, A.; Lacroix, L.; Billot, K.; Baud, V.; Thiery, J.; Vielh, P.; Terrier, P.; Wiels, J.; Vassilev, L.; Lecesne, A.; Bonvalot, S.; Chouaib, S. Attenuation of soft-tissue sarcomas resistance to the cytotoxic action of TNF-alpha by restoring p53 function. PloS One, 2012, 7(6), e38808.
120. Henze, J.; Muhlenberg, T.; Simon, S.; Grabellus, F.; Rubin, B.; Taeger, G.; Schuler, M.; Treckmann, J.; Debiec-Rychter, M.; Taguchi, T.; Fletcher, J.A.; Bauer, S. p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors. PloS One, 2012, 7(5), e37776.
121. Tovar, C.; Higgins, B.; Kolinsky, K.; Xia, M.; Packman, K.; Heimbrook, D.C.; Vassilev, L.T. MDM2 antagonists boost antitumor effect of androgen withdrawal: Implications for therapy of prostate cancer. Mol. Cancer, 2011, 10, 49.
122. Azmi, A.S.; Beck, F.W.; Sarkar, F.H.; Mohammad, R.M. Network perspectives on HDM2 inhibitor chemotherapy combinations. Curr. Pharm. Des., 2011, 17(6), 640-652.
123. Ray-Coquard, I.; Blay, J.Y.; Italiano, A.; Le Cesne, A.; Penel, N.; Zhi, J.; Heil, F.; Rueger, R.; Graves, B.; Ding, M.; Geho, D.; Middleton, S.A.; Vassilev, L.T.; Nichols, G.L.; Bui, B. N. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: An exploratory proof-of-mechanism study. Lancet Oncol., 2012, 13(11), 1133-1140.
124. ClinicalTrials.gov. A service of the U.S. National Institutes of Health. http://www.clinicaltrials.gov/. (Accessed November, 2012)
125. Houghton, P.J.; Morton, C.L.; Tucker, C.; Payne, D.; Favours, E.; Cole, C.; Gorlick, R.; Kolb, E.A.; Zhang, W.; Lock, R.; Carol, H.; Tajbakhsh, M.; Reynolds, C.P.; Maris, J.M.; Courtright, J.; Keir, S.T.; Friedman, H. S.; Stopford, C.; Zeidner, J.; Wu, J.; Liu, T.; Billups, C.A.; Khan, J.; Ansher, S.; Zhang, J.; Smith, M.A. The pediatric preclinical testing program: Description of models and early testing results. Pediatr. Blood Cancer, 2007, 49(7), 928-940. (Pubitemid 350022448)
126. Smith, M.A.; Gorlick, R.; Kolb, E.A.; Lock, R.; Carol, H.; Maris, J.M.; Keir, S.T.; Morton, C.L.; Reynolds, C.P.; Kang, M.H.; Arts, J.; Bashir, T.; Janicot, M.; Kurmasheva, R.T.; Houghton, P.J. Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. Pediatr. Blood Cancer, 2012, 59(2), 329-332.
127. Carol, H.; Reynolds, C.P.; Kang, M.H.; Keir, S.T.; Maris, J.M.; Gorlick, R.; Kolb, E.A.; Billups, C.A.; Geier, B.; Kurmasheva, R.T.; Houghton, P.J.; Smith, M.A.; Lock, R.B. Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program. Pediatr. Blood Cancer, 2012.2012 Jul 2. doi: 10.1002/pbc.24235. [Epub ahead of print]